Bora CDMO Bora CDMO

X

Find Drugs in Development News & Deals for Birinapant

PharmaCompass
API SUPPLIERS
API Suppliers

API Suppliers

0

US DMFs Filed

US DMFs Filed

0

CEP/COS Certifications

CEP/COS Certifications

0

JDMFs Filed

JDMFs Filed

0

Other Certificates

Other Certificates

0

Other Suppliers

Other Suppliers

0

API REF. PRICE (USD / KG)

0

INTERMEDIATES

0

DOSSIERS // FDF
USA (Orange Book)

USA (Orange Book)

0

Europe

Europe

0

Canada

Canada

0

Australia

Australia

0

South Africa

South Africa

0

Uploaded Dossiers

Uploaded Dossiers

0

GLOBAL SALES (USD Million)

U.S. Medicaid

0

Annual Reports

0

EXCIPIENTS

0

PATENTS & EXCLUSIVITIES

USFDA Orange Book Patents

0

USFDA Exclusivities

0

DIGITAL CONTENT

Blog #PharmaFlow

0

News

REF STANDARD

EDQM

0

USP

0

JP

0

Other Listed Suppliers

0

SERVICES

0

Details:

Company initiated its clinical study in solid cancers with birinapant (IGM-9427) in combination with IGM’s DR5 agonist antibody IGM-8444. The purpose of this first clinical trial with the combination will be to explore safety and tolerability.


Lead Product(s): Birinapant,IGM-8444

Therapeutic Area: Oncology Product Name: TL32711

Highest Development Status: Phase IProduct Type: Small molecule

Partner/Sponsor/Collaborator: IGM Biosciences

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable November 04, 2021

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

IGM will receive global, exclusive development and commercialization rights for birinapant, a clinical-stage SMAC mimetic that binds to and degrades Inhibitors of Apoptosis Proteins (IAPs), leading to cell death (apoptosis) in tumor cells.


Lead Product(s): Birinapant,IGM-8444

Therapeutic Area: Oncology Product Name: TL32711

Highest Development Status: PreclinicalProduct Type: Small molecule

Partner/Sponsor/Collaborator: IGM Biosciences

Deal Size: $352.5 million Upfront Cash: $1.0 million

Deal Type: Licensing Agreement January 11, 2021

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content
  • Deals

Details:

The original agreement between Medivir and TetraLogic included milestone payments with predetermined amounts as well as royalty obligations to TetraLogic if and when Medivir develops, markets or out-licenses birinapant further.


Lead Product(s): Birinapant

Therapeutic Area: Oncology Product Name: TL32711

Highest Development Status: Phase IProduct Type: Small molecule

Partner/Sponsor/Collaborator: Medivir

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Agreement December 11, 2020

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty
Post Enquiry
POST ENQUIRY